PAREXEL International Corporation , a global biopharmaceutical services company and provider of clinical research and logistics, recently announced the launch of its patient sensor solution. The solution securely captures, transmits, stores and visualizes study subject data in clinical trials.
Stock Performance
The price performance of PAREXEL International was unfavorable in the last three months. The stock lost 4.18%, underperforming the Zacks classified Medical Services sub-industry’s gain of almost 0.38%.
Also, the estimate revision trend for the current year was unfavorable in the last two months. Two estimates moved south against no movement in the opposite direction. This justifies the stock’s Zacks Rank #4 (Sell).
Patient Sensor Solution in Detail
Coming back to the news, the newly launched patient sensor solution is powered by the proprietary Perceptive MyTrials Analytics platform. This enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices. Also, the use of wearables and sensors reduce the number of clinical assessments and/or on-site visits during clinical trials.
Going forward, we believe PAREXEL primarily aims at diversifying its core business through launches like this. In fact, the company is striving to come up with a single solution for all the clinical development outsourcing needs of clients by unifying the highly advanced tasks of clinical monitoring, data management, biostatistics, site monitoring, study management, medical writing and pharma covigilance.
Meanwhile, the biopharmaceuticals market is forecast to grow at a CAGR of 9.4% to reach a worth of $278 billion by 2020, per Persistence Market Research. We expect PAREXEL to gain significant traction in the biopharmaceutical and related ancillary markets, courtesy of the favorable trend and the takeover.
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Fluidigm Corporation . Notably, Inogen and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.
IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an impressive 97.5% over the last one year.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
PAREXEL International Corporation , a global biopharmaceutical services company and provider of clinical research and logistics, recently announced the launch of its patient sensor solution. The solution securely captures, transmits, stores and visualizes study subject data in clinical trials.
Stock Performance
The price performance of PAREXEL International was unfavorable in the last three months. The stock lost 4.18%, underperforming the Zacks classified Medical Services sub-industry’s gain of almost 0.38%.
Also, the estimate revision trend for the current year was unfavorable in the last two months. Two estimates moved south against no movement in the opposite direction. This justifies the stock’s Zacks Rank #4 (Sell).
Patient Sensor Solution in Detail
Coming back to the news, the newly launched patient sensor solution is powered by the proprietary Perceptive MyTrials Analytics platform. This enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices. Also, the use of wearables and sensors reduce the number of clinical assessments and/or on-site visits during clinical trials.
Going forward, we believe PAREXEL primarily aims at diversifying its core business through launches like this. In fact, the company is striving to come up with a single solution for all the clinical development outsourcing needs of clients by unifying the highly advanced tasks of clinical monitoring, data management, biostatistics, site monitoring, study management, medical writing and pharma covigilance.
Meanwhile, the biopharmaceuticals market is forecast to grow at a CAGR of 9.4% to reach a worth of $278 billion by 2020, per Persistence Market Research. We expect PAREXEL to gain significant traction in the biopharmaceutical and related ancillary markets, courtesy of the favorable trend and the takeover.
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Fluidigm Corporation . Notably, Inogen and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.
IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an impressive 97.5% over the last one year.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on IDXX - FREE
Get the latest research report on INGN - FREE